Nurse Practitioner Program year 2024 Source: CMS Open Payments, 2026 publication

Michelle Rogers Kull

Nurse Practitioner Rochester, MN Nurse Practitioner

NPI 1437799319 CMS profile 11246530

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$42

1 record reported · program year 2024

Research payments

$0

Paid to them · None reported · program year 2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michelle Rogers Kull of Rochester, MN is reported in the CMS Open Payments database as having received $42 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 14th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2024 General $42 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Rogers Kull
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michelle Rogers Kull were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michelle Rogers Kull Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $42 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2024
  1. ACADIA Pharmaceuticals Inc $42 1 payment

Every payment, record by record

What the payments were for General payments · program year 2024
  1. Food and Beverage $42 1 payment
Products named General payments · program year 2024
  1. NUPLAZID $42 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

672

Median for Nurse Practitioner: 389

Drug cost

$3,874,891

Median for Nurse Practitioner: $21,885

Branded share of claims

40.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 139 $2,470,536
Pomalyst Pomalidomide Brand 35 $789,113
Lenalidomide Generic 26 $362,690
Venclexta Venetoclax Brand 18 $236,675
Eliquis Apixaban Brand 15 $9,694
Acyclovir Generic 114 $1,647
Dexamethasone Generic 97 $1,264
Granisetron Hcl Generic 11 $988
Valacyclovir Valacyclovir Hcl Brand 17 $370
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 39 $344

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$923,573

Of which drugs: $859,639

Medicare patients

460

Average age 72

Services billed

57,543

263 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 45%
Chronic kidney disease 37%
Osteoporosis 28%
Diabetes 24%
Depression 24%
Ischemic heart disease 22%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 42 6,460 $221,493
Injection, vedolizumab, 1 mg J3380 Office 16 6,900 $118,418
Injection, romosozumab-aqqg, 1 mg J3111 Office 28 9,870 $82,321
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg Q5121 Office 24 2,520 $48,465
Injection, tocilizumab, 1 mg J3262 Office 11 9,000 $42,877
Injection, remdesivir, 1 mg J0248 Office 55 8,000 $37,408
Injection, methylprednisolone sodium succinate, up to 40 mg J2920 Office 22 30 $98
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 19 388 $83

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
  • ACADIA Pharmaceuticals Inc $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record